Show simple item record

dc.contributor.authorLage Fernández, Ricardo
dc.contributor.authorCebro Márquez, María
dc.contributor.authorRodríguez Mañero, Moises 
dc.contributor.authorGonzález Juanatey, José Ramón 
dc.contributor.authorMoscoso Galán, Isabel
dc.date.accessioned2021-10-13T10:48:18Z
dc.date.available2021-10-13T10:48:18Z
dc.date.issued2019
dc.identifier.issn1932-6203
dc.identifier.otherhttps://www.ncbi.nlm.nih.gov/pubmed/30794687
dc.identifier.otherhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6386316/pdf/pone.0212782.pdf
dc.identifier.urihttp://hdl.handle.net/20.500.11940/15487
dc.description.abstractBACKGROUND: Association between obesity and cardiovascular diseases is well known, however increased susceptibility of obese patients to develop several cancer types is not so commonly known. Current data suggest that poorer overall survival in cancer patients might be associated to non-cancer-related causes such as higher risk of cardiotoxicity in obese patients treated with chemotherapeutic agents. Omentin, a novel adipokine decreased in obesity, is actually in the spotlight due to its favourable effects on inflammation, glucose homeostasis and cardiovascular diseases. Also, recent data showed that in vitro anthracycline-induced cardiomyocyte apoptosis is counteracted by omentin suggesting its cardioprotective role. OBJECTIVE: Our aim was to evaluate omentin effects against docetaxel toxicity. RESULTS: Our data indicate that omentin inhibits docetaxel-induced viability loss and that increased viability is associated to decreased caspase-3 expression and cell death. Although omentin reduces NOX4 expression, it failed to reduce docetaxel-induced reactive oxygen species production. Our results indicate that omentin decreases docetaxel-induced endoplasmic reticulum stress, suggesting that cardioprotective role might be associated to ERS inhibition. CONCLUSION: These data suggest that omentin treatment may contribute to decrease susceptibility to DTX-induced cardiotoxicity.
dc.rightsAtribución 4.0 Internacional
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.titleOmentin protects H9c2 cells against docetaxel cardiotoxicity
dc.typeArtigoes
dc.authorsophosGonzález Juanatey, José Ramón
dc.authorsophosRodríguez Mañero, Moises
dc.authorsophosMoscoso Galán, Isabel
dc.authorsophosLage Fernández, Ricardo
dc.authorsophosCebro Márquez, María
dc.identifier.doi10.1371/journal.pone.0212782
dc.identifier.pmid30794687
dc.identifier.sophos30825
dc.issue.number2
dc.journal.titlePLoS One
dc.organizationServizo Galego de Saúde::Estrutura de Xestión Integrada (EOXI)::EOXI de Santiago de Compostela - Complexo Hospitalario Universitario de Santiago de Compostela::Cardioloxía
dc.organizationServizo Galego de Saúde::Estrutura de Xestión Integrada (EOXI)::Instituto de Investigación Sanitaria de Santiago de Compostela (IDIS)
dc.page.initiale0212782es
dc.rights.accessRightsopenAccess
dc.subject.keywordCHUS
dc.subject.keywordIDIS
dc.typefidesArtículo Científico (incluye Original, Original breve, Revisión Sistemática y Meta-análisis)
dc.typesophosArtículo Original
dc.volume.number14


Files in this item

This item appears in the following Collection(s)

Show simple item record

Atribución 4.0 Internacional
Except where otherwise noted, this item's license is described as Atribución 4.0 Internacional